

# FDA-AUTHORIZED ORAL MEDICATIONS FOR TREATMENT OF COVID-19 IN **NON-HOSPITALIZED** PATIENTS

**Oral antiviral medications** are FDA authorized for COVID-19. These medications work by interfering with the ability of the COVID-19 virus to replicate inside the body. This lowers the “viral load,” which is the amount of virus doctors find in your body. This can help reduce the severity of COVID-19 symptoms and shorten the length of the illness.

*This table is for informational purposes only. Treatments require a prescription and should be guided by a patient’s healthcare team.*

## Paxlovid<sup>1</sup> (nirmatrelvir and ritonavir tablets)

Important note: Paxlovid may impair the efficacy and safety of certain cancer medications. It should be used with the guidance of your oncologist

<b>Authorized for</b>	Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in <u>non-hospitalized patients</u> who are at high risk of progression to severe infection (such as blood cancer patients and survivors)  Paxlovid treatment is not <ul style="list-style-type: none"> <li>• For use in preventing COVID-19 infection</li> <li>• Authorized for use longer than 5 consecutive days</li> </ul>
<b>Ages</b>	Adults 18 years and older  Children 12 and up who weigh at least 88 pounds
<b>Activity against Omicron</b>	Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients <sup>2,3</sup>
<b>Dosing/Timing</b>	<ul style="list-style-type: none"> <li>• Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset</li> <li>• Three tablets (2 nirmatrelvir and 1 ritonavir) taken together twice daily for 5 days</li> <li>• Can be taken with or without food</li> </ul>
<b>Manufacturer</b>	Pfizer  To read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers, visit: <a href="https://www.covid19oralrx-patient.com/files/Final-EUA-Fact-sheet-for-Patients-Parents-and-Caregivers-COVID-19-Oral-Antiviral.pdf">https://www.covid19oralrx-patient.com/files/Final-EUA-Fact-sheet-for-Patients-Parents-and-Caregivers-COVID-19-Oral-Antiviral.pdf</a>

## Lagevrio<sup>4</sup> (molnupiravir)

<b>Authorized for</b>	Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors)  Lagevrio treatment is not <ul style="list-style-type: none"> <li>• For use in preventing COVID-19 infection</li> <li>• Authorized for use longer than 5 consecutive days</li> </ul>
<b>Ages</b>	Adults 18 years and older
<b>Activity against Omicron</b>	Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients <sup>2,3</sup>
<b>Dosing/Timing</b>	<ul style="list-style-type: none"> <li>• Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset</li> <li>• Four capsules taken every 12 hours for 5 days</li> <li>• Can be taken with or without food</li> </ul>
<b>Manufacturer</b>	Merck & Co., Inc.  To read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers, visit: <a href="https://www.merck.com/eua/molnupiravir-patient-fact-sheet-english.pdf">https://www.merck.com/eua/molnupiravir-patient-fact-sheet-english.pdf</a>

1. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid

2. Dabrowska A et al. Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.

3. Vangeel L et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern.

4. Fact sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir